Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
A representative image illustrating Mapi Pharma’s once-monthly Cariprazine Depot research after initial Phase I/IIa results supported continued development of the long-acting injectable treatment for schizophrenia and other psychiatric disorders.
Pharma & Biotech

Once-monthly Cariprazine Depot clears first clinical safety test as Mapi targets 2029 NDA

Cariprazine Depot clears its first clinical safety hurdle as Mapi targets a U.S. IND in 2026 and potential 2029 NDA. See what comes next.

Read More
A representative image illustrating NeOnc Technologies Holdings’ NEO100 research after the intranasal therapy met its Phase 2a progression-free survival endpoint in recurrent IDH1-mutant high-grade glioma.
Pharma & Biotech

NEO100 reaches 48.9% six-month progression-free survival in difficult brain cancer

NEO100 hits its Phase 2a glioma endpoint with 48.9% six-month PFS. See why FDA talks, trial design and funding now become critical.

Read More
Signature Biologics’ FDA-cleared enrollment expansion could allow up to 30 additional participants in its investigational UC-MSC program for Duchenne muscular dystrophy, broadening the clinical dataset while safety and efficacy remain under evaluation. Representative image.
Pharma & Biotech

What FDA expanded enrollment means for Signature Biologics’ Duchenne cell therapy program

FDA allows up to 30 more patients in Signature Biologics’ DMD UC-MSC program, expanding access while efficacy remains unproven.

Read More
Adaptyx Biosciences and Attune Neurosciences are studying whether wearable molecular sensing and neuromodulation data can help identify objective biomarkers linked to chronic pain and treatment response. Representative image.
Medical Devices & Diagnostics

Can a wearable make chronic pain measurable? Adaptyx and Attune put five biomarkers to the test

Adaptyx and Attune begin a $4 million ARPA-H-backed study testing continuous biomarkers and focused ultrasound in 100 adults with chronic pain.

Read More
VB Spine’s acquisition of Augmedics’ CT-Fluoro technology could broaden use of the xvision augmented reality spine navigation platform by combining preoperative CT imaging with intraoperative 2D fluoroscopy. Representative image.
Medical Devices & Diagnostics

VB Spine closes Augmedics CT-Fluoro deal as xvision targets wider AR spine surgery adoption

VB Spine has closed its CT-Fluoro deal with Augmedics. See why the xvision addition could widen access to AR spine navigation.

Read More
Alfasigma’s planned acquisition of Nordic Group is set to expand its European specialty-care presence, adding Nordic Pharma’s rheumatology portfolio, including Nordimet, alongside operations across Europe, Canada and Japan. Representative image.
Pharma & Biotech

Alfasigma’s Nordic Pharma deal is more than a bolt-on: why the €190m business could reshape its specialty-care strategy

Alfasigma will acquire Nordic Group, adding Nordimet, €190 million in revenue and broader specialty-care operations across Europe, Canada and Japan.

Read More
Belenos Biosciences’ BEL512 has delivered positive Phase 2 results in chronic rhinosinusitis with nasal polyps, supporting further development of the long-acting bispecific antibody as the company prepares for Phase 3 testing. Representative image.
Pharma & Biotech

What do BEL512 Phase 2 results mean for Belenos Biosciences and CRSwNP treatment?

Belenos says BEL512 met all Phase 2 CRSwNP endpoints, but undisclosed effect sizes make the planned 2027 Phase 3 trial the critical test.

Read More
AgelessRx advances its healthy aging research after securing a $1 million XPRIZE Healthspan award, with a larger clinical trial set to evaluate muscle, cognitive and immune function in older adults. Representative image.
Pharma & Biotech

Can a multi-drug longevity protocol really slow functional aging? AgelessRx just won $1m to test it

AgelessRx wins $1 million from XPRIZE Healthspan to expand its multi-therapy longevity approach into a larger one-year clinical trial.

Read More
Silence Therapeutics’ $175 million public offering strengthens its funding position as divesiran advances toward planned Phase 3 development in polycythemia vera. Representative image.
Pharma & Biotech

Silence Therapeutics raised $175m right after SANRECO success. What does it unlock for divesiran?

Silence Therapeutics raises $175 million after positive divesiran Phase 2 data, strengthening funding ahead of a planned Phase 3 PV trial.

Read More
AN2 Therapeutics is advancing a broader boron-based drug pipeline, with Phase 2 programs targeting polycythemia vera, Mycobacterium abscessus lung disease and Chagas disease as the company enters a critical clinical execution period. Representative image.
Pharma & Biotech

AN2 Therapeutics is betting on three Phase 2 programs, but can its boron pipeline deliver after epetraborole’s MAC setback?

AN2 Therapeutics is advancing three Phase 2 programs as epetraborole moves into PV and AN2-502998 approaches a Chagas proof-of-concept test.

Read More